(Albany, USA) DelveInsight’s Developmental and Epileptic Encephalopathy Market Insights report includes a comprehensive understanding of current treatment practices, developmental and epileptic encephalopathy emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Developmental and Epileptic Encephalopathy Market Report
Discover which therapies are expected to grab the major developmental and epileptic encephalopathy market share @ Developmental and Epileptic Encephalopathy Market Forecast
Developmental and Epileptic Encephalopathy Overview
Developmental and epileptic encephalopathy is a seizure disorder characterized by infantile spasms, a type of seizure. Spasms typically appear before the age of one. The prognosis for developmental and epileptic encephalopathy is bleak. This rare disease, typically described as progressive and incurable, is also associated with severe physical and cognitive disabilities and unexplained death.
The most common cause of epileptic encephalopathy in childhood is structural abnormalities, which can be congenital (such as cortical malformations) or acquired (such as hypoxic-ischemic after the EEG often evolves to atypical hypsarrhythmia, which is a transient or multifocal spike and sharp waves 3-4 months after the onset of the disease. The diagnosis of these epileptic encephalopathies begins with an EEG which should include both the sleep and wake states.
Developmental and Epileptic Encephalopathy Epidemiology Segmentation
DelveInsight estimates that there were approximately 235K diagnosed prevalent cases of DEE in the 7MM in 2021.
Among the EU-4 countries, the diagnosed prevalent population of DEE was maximum in Germany in 2021.
The developmental and epileptic encephalopathy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Download the report to understand which factors are driving developmental and epileptic encephalopathy epidemiology trends @ https://www.delveinsight.com/report-store/developmental-and-epileptic-encephalopathies-dee-market
Developmental and Epileptic Encephalopathy Treatment Market
Some of the general principles and approach to pediatric epilepsy treatment can be found in the epileptic encephalopathy treatment. The best anti-epileptic treatment is chosen based on the type of epilepsy syndrome. Although anti-seizure medications are commonly used, some types of seizures are notoriously difficult to control. It is the primary method of controlling epileptic seizures and is almost always the first class of therapy medications.
Some of the FDA-approved drugs used for DEE treatment include Epidiolex (Jazz Pharmaceuticals), Diacomit (Biocodex), Fintepla (Zogenix), Sabril (Lundbeck), Ztalmy (Marinus Pharmaceuticals), Afinitor Disperz/Votubia (Novartis), Sympazan (Aquestive Therapeutics), Trokendi XR (Supernus Pharmaceuticals), Onfi (Lundbeck), Banzel (Eisai Pharmaceuticals), Lamictal (GlaxoSmithKline), and others.
In some children, steroid therapy with adrenocorticotropic hormone (ACTH) or prednisone has been beneficial. When medications do not work well, a vagus nerve stimulator or the ketogenic diet may be considered in patients. Moreover, in children with seizures that begin in one area or involve only one side of the brain, epilepsy surgery may be an option. In these cases, a focal resection (removal of a single area) or a hemispherectomy (removal of the majority of one side of the brain) may be considered.
To know more about developmental and epileptic encephalopathy treatment options, visit @ Developmental and Epileptic Encephalopathy Treatment Market
Developmental and Epileptic Encephalopathy Pipeline Therapies and Key Companies
Learn more about the DEE FDA-approved drugs @ Developmental and Epileptic Encephalopathy Drugs Market
Developmental and Epileptic Encephalopathy Market Dynamics
The dynamics of developmental and epileptic encephalopathy market is anticipated to change in the coming years. Ztalmy, the first licensed therapy for CDKL5 deficiency disorder, was recently approved in the United States, boosting the developmental and epileptic encephalopathy market growth. Moreover, the void left by a lack of licensed medications will be filled by further R&D advancement. In addition, Epidiolex and Fintepla continue to add new prescribers and expand their existing prescriber base due to their strong uptake.
Furthermore, the current competitive scenario for DEE is limited to a few therapies. Currently, the DEE market appears to be an unexplored area by pharmaceutical companies, and thus the companies have a significant opportunity to capture the potential developmental and epileptic encephalopathy market space. Emerging drugs with improved seizure control may positively impact the developmental and epileptic encephalopathy market landscape and patients’ quality of life.
However, several factors are impeding the growth of the DEE market. Rare epileptic syndromes, such as LGS, Dravet Syndrome, and CDKL5 deficiency disorder, are extremely complex and heterogeneous diseases with multiple etiologies, posing several diagnostic challenges as the disease progresses.
Scope of the Developmental and Epileptic Encephalopathy Market Report
Discover more about DEE drugsin development @ Developmental and Epileptic Encephalopathy Clinical Trials
Table of Contents
1
Key Insights
2
Developmental and Epileptic Encephalopathy Report Introduction
3
Executive Summary
4
Key Events
5
Developmental and Epileptic Encephalopathy SWOT Analysis
6
Developmental and Epileptic Encephalopathy Epidemiology and Market Methodology
7
Developmental and Epileptic Encephalopathy (DEE) Market Overview at a Glance
7.1
Developmental and Epileptic Encephalopathy Market Share (%) Distribution by Therapies in 2021
7.2
Developmental and Epileptic Encephalopathy Market Share (%) Distribution by Therapies in 2034
8
Developmental and Epileptic Encephalopathy Background and Overview
8.1
West Syndrome
8.2
Dravet Syndrome
8.3
Lennox–Gastaut Syndrome
8.4
Landau–Kleffner Syndrome (LKS) (Acquired Epileptic Aphasia)
8.5
Epilepsy with Continuous Spike-and-Waves during Slow-Wave Sleep
8.6
Doose Syndrome (myoclonic atonic epilepsy)
8.7
CDKL5 deficiency disorder (CDD)
8.8
Tuberous sclerosis complex (TSC)
8.9
Genetic Epilepsy
8.10
Biomarkers of epileptic encephalopathies
9
Treatment of Developmental and Epileptic Encephalopathy
9.1
Antiseizure medications
9.2
Steroid therapy
9.3
Other Therapies
9.4
Epilepsy surgery
9.5
Developmental and Epileptic Encephalopathy Treatment Algorithm
10
Developmental and Epileptic Encephalopathy Treatment Guidelines
11
Developmental and Epileptic Encephalopathy Epidemiology and Patient Population of 7MM
11.1
Key Findings
11.2
Assumptions and Rationale
11.2.1
11.2.2
Lennox-Gastaut Syndrome
11.2.3
Ohtahara Syndrome
11.2.4
11.2.5
Landau-Kleffner Syndrome
11.2.6
Tuberous Sclerosis Complex
11.2.7
CDKL5 deficiency disorder
11.2.8
Others
11.3
Diagnosed Prevalent Population of DEE in 7MM
11.4
United States
11.4.1
Diagnosed Prevalent Population of DEE in the United States
11.5
EU-4 and UK
11.5.1
Diagnosed Prevalence of DEE in the EU-4 and the UK
11.6
Japan
11.6.1
Diagnosed Prevalent Population of Developmental and Epileptic Encephalopathy in Japan
12
Marketed Developmental and Epileptic Encephalopathy Drugs
12.1
Key Competitor
13
Emerging Developmental and Epileptic Encephalopathy Drugs
13.1
Key Competitors
14
Developmental and Epileptic Encephalopathy (DEE): 7MM Market Analysis
14.1
14.2
Developmental and Epileptic Encephalopathy Market Outlook
14.3
Key Market Forecast Assumptions
14.4
Attribute Analysis
14.5
Total Market Size of Developmental and Epileptic Encephalopathy in the 7MM
14.6
Developmental and Epileptic Encephalopathy Market Size by Current and Emerging Therapies in the 7MM
14.7
United States Market Size
14.7.1
Total Market Size of DEE in the United States
14.7.2
Market Size of DEE by Current and Emerging Therapies in the United States
14.8
EU-4 and UK Market Size
14.8.1
Total Market size of DEE in the EU-4 and the UK
14.8.2
Market Size of DEE by Current and Emerging Therapies in EU-4 and the UK
14.9
14.9.1
Total Market size of DEE in Japan
14.9.2
Market Size of DEE by Current and Emerging Therapies in Japan
15
Developmental and Epileptic Encephalopathy Market Drivers
16
Developmental and Epileptic Encephalopathy Market Barriers
17
Developmental and Epileptic Encephalopathy Unmet Needs
18
Developmental and Epileptic Encephalopathy Market Access and Reimbursement
19
Appendix
19.1
Bibliography
19.2
Report Methodology
20
DelveInsight Capabilities
21
Disclaimer
22
About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/consulting
